The S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.76% to 8,003.8 points in early trading on Tuesday.
As reported in The Australian, 3 All Ords stocks have just gained buy ratings from top brokers.
Let's check them out.
Capstone Copper Corp CDI (ASX: CSC)
ASX All Ords copper shares are benefiting from the global focus on future decarbonisation. Copper is a key material required in electric vehicles, wind turbines, and solar energy systems.
It's also an essential building material for data centres, which is an explosive growth segment of the property market supporting today's global artificial intelligence boom.
Copper futures rose to a record high of US$5.20 per pound last month but have since retreated to US$4.45 per pound on fears that short-term demand in China may fall due to lower industrial output.
The long-term outlook for copper is still very positive, though.
Most experts say that gradually rising demand as decarbonisation grows, set against a looming lack of supply due to the high cost of starting new copper mines, will keep the commodity price rising over time.
Copper futures remain 17.7% higher than this time last year, and top broker Goldman Sachs has a year-end price target of US$5.44 per pound.
This all bodes well for the dual-listed Canadian-based Capstone Copper, which only began trading on the ASX in April.
Macquarie has commenced coverage on the ASX All Ords copper share with an outperform rating and a 12-month price target of $9.80.
At the time of writing, the Capstone Copper share price is already higher than the target at $10.02, up 2.24% for the day so far.
Integral Diagnostics Ltd (ASX: IDX)
Integral Diagnostics is an ASX All Ords healthcare share. The company provides medical imaging services.
Yesterday, Integral Diagnostics announced it had made an offer to merge with competitor Capitol Health Ltd (ASX: CAJ).
Investors weren't too impressed with the all-scrip offer, and the ASX All Ords healthcare share fell 4.14% to close at $2.43 yesterday.
A rebound is occurring today, with the Integral Diagnostics share price up 4.53% to $2.54 at the time of writing.
Meantime, JP Morgan is backing the ASX All Ords healthcare share for growth.
The broker has raised its rating on the stock to overweight, with a 12-month price target of $2.80.
Life360 Inc (ASX: 360)
Canaccord has started coverage on this popular ASX All Ords technology share with a buy rating.
The broker has a 12-month share price target of $40 on the stock.
UBS has also started coverage on Life360, but it's less ambitious about potential share price growth.
The broker has a neutral rating on Life360 shares and a $32 share price target. Still, that's more than double the current share price.
The ASX All Ords tech share is changing hands for $15.30 apiece today, down 0.91% at the time of writing.
Life360 is the location technology company behind the Life360 app, which millions of families worldwide use to keep track of each other.
As my colleague James reports, Life360's monthly active users increased by 4.9 million during the first quarter to 66.4 million.
This is boosting revenue amid management's efforts to increase average revenue per user and the number of paid subscribers.
